Determining Clinical Course of Diffuse Large B-Cell Lymphoma Using Targeted Transcriptome and Machine Learning Algorithms
Maher Albitar(Center for Genomic Science), Ken H. Young(Duke Medical Center), Michael Møller(Hospital South West Jutland), Karen Dybkær(Aalborg University Hospital), Govind Bhagat(Columbia University Irving Medical Center), Benjamin M. Parsons(Gundersen Health System), Maurilio Ponzoni(San Raffaele University of Rome), Bing Xu(First Affiliated Hospital of Xiamen University), Feng Zhu(Xuzhou Medical College), Eric D. Hsi(Mayo Clinic), Zijun Y. Xu‐Monette(Duke University), Alexandar Tzankov(University of Basel), Carlo Visco(University of Verona), April Chiu(Mayo Clinic), Youli Zu(Methodist Hospital), Wayne Tam(Cornell University), Miguel Á. Piris(Hospital Universitario Fundación Jiménez Díaz), Xiaosheng Fang(Shandong Provincial Hospital), Andrés J.M. Ferreri(Vita-Salute San Raffaele University), Jooryung Huh(Asan Medical Center), André Goy(Hackensack University Medical Center), Yong Li(Baylor College of Medicine), Hong Zhang(Second Affiliated Hospital of Xi'an Jiaotong University), Jane N. Winter(Northwestern University), Joannes H.J.M. Van Krieken(Radboud University Nijmegen), Fredrick B. Hagemeister(The University of Texas MD Anderson Cancer Center)
Cited by 2
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2020|1.9k
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2013|1.7k